Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2/5-hPDE6B gene therapy in PDE6B-related retinitis pigmentosa
NCT03328130Phase 2Terminated
- Sponsor
- eyeDNA Therapeutics
- Start
- Nov 2017
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of AAV2/5-hPDE6B in retinitis pigmentosa (RP), sponsored by eyeDNA Therapeutics. Started Nov 2017; status: terminated.
02
Drugs
AAV2/5-hPDE6B
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT03328130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328130.